Dextera Surgical (DXTR) Stock Rating Upgraded by Zacks Investment Research
Dextera Surgical (NASDAQ:DXTR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.
According to Zacks, “Dextera Surgical Inc. designs and manufactures proprietary stapling devices for surgical procedures. The company’s product consists of MicroCutter 5/80 use for transection and resection in urologic, thoracic and pediatric surgical procedures, as well as application for transection, resection and/or creation of anastomoses in the intestine and the transection of the appendix. Dextera Surgical Inc., formerly known as Cardica Inc., is headquartered in Redwood City, California. “
Separately, Ladenburg Thalmann Financial Services initiated coverage on shares of Dextera Surgical in a report on Wednesday, August 16th. They set a “buy” rating and a $0.80 price target for the company.
Shares of Dextera Surgical (NASDAQ:DXTR) traded down $0.02 on Tuesday, reaching $0.07. 9,564,960 shares of the company traded hands, compared to its average volume of 2,234,717. Dextera Surgical has a 1 year low of $0.05 and a 1 year high of $2.33.
Dextera Surgical (NASDAQ:DXTR) last posted its quarterly earnings results on Thursday, November 9th. The medical instruments supplier reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02). The business had revenue of $0.69 million for the quarter, compared to the consensus estimate of $0.62 million. analysts predict that Dextera Surgical will post -0.25 earnings per share for the current year.
An institutional investor recently raised its position in Dextera Surgical stock. Broadfin Capital LLC grew its stake in Dextera Surgical Inc (NASDAQ:DXTR) by 64.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 987,520 shares of the medical instruments supplier’s stock after buying an additional 388,080 shares during the period. Broadfin Capital LLC owned 11.06% of Dextera Surgical worth $296,000 at the end of the most recent reporting period. Institutional investors own 4.49% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Dextera Surgical (DXTR) Stock Rating Upgraded by Zacks Investment Research” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/dextera-surgical-dxtr-stock-rating-upgraded-by-zacks-investment-research/1763672.html.
Dextera Surgical Company Profile
Dextera Surgical Inc, formerly Cardica, Inc, designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons.
Receive News & Ratings for Dextera Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dextera Surgical and related companies with MarketBeat.com's FREE daily email newsletter.